Abstract: Compounds of the formula ##STR1## wherein one of the radicals R.sup.1, R.sup.2 or R.sup.3 denotes a straight-chain alkyl group having 4 to 8 C atoms and two vicinal hydroxyl groups in the .omega.,.omega.-1 or .omega.-1,.omega.-2 positions and the two other radicals represent straight-chain or branched alkyl groups having up to 12 C atoms in the position of R.sup.1 and R.sup.3 and up to 4 C atoms in the position of R.sup.2, the total of C atoms in these two alkyl substituents being a maximum of 14, are prepared by oxidation of the corresponding alkenylxanthines and by alkylation with compounds which introduce the dihydroxyalkyl radical or a precursor thereof. The dihydroxyalkyldialkylxanthines are suitable for the treatment of obstructive respiratory tract diseases.

Abstract: Certain functionalized cogeners of 1,3-dialkylxanthine exhibit high potency and selectivity as antagonists for A.sub.1 - and A.sub.2 -adenosine receptors and are suitable for attachment to probes, drug carriers, or solid supports. These derivatives are characterized by the presence of a phenyl at the 8 position para-substituted with a functionalized chain to provide high water solubility and high receptor affinity. Some of these analogs, containing a distal amino- or carboxylic-functionalized chain, are suitable for synthesis of amino acid conjugates. The compounds of this invention are suitable for use as antiallergenic, antiasthmatic, or cardiotonic drugs, central nervous system stimulants, and diuretics.

Abstract: A novel theophylline-7- acetic acid ester is described. Said ester is obtained by reacting, at a temperature from 1.degree. to 20.degree. C., theophylline-7-acetic acid chloride with d,l-trans-sobrerol.There are further described pharmaceutical compositions with mucosecretolytic-fluidizing and antibronchospastic activity containing the novel ester.

Abstract: Compounds having activity against chronic obstructive airway disease or cardiac disease, characterized by the formula ##STR1## wherein R.sup.1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R.sup.2 is hydrogen or methyl, provided that R.sup.2 is methyl when R.sup.1 is n-propyl, n-butyl or isobutyl, or a physiologically acceptable salt thereof.

Abstract: Certain functionalized congeners of 1,3-dialkylxanthine exhibit high potency and selectivity as antagonists for A.sub.1 - and A.sub.2 -adenosine receptors and are suitable for attachment to probes, drug carriers, or solid supports. These derivatives are characterized by the presence of a phenyl at the 8 position para-substituted with a functionalized chain to provide high water solubility and high receptor affinity to such an extent that these compounds are suitable for use as antiallergenic, antiasthmatic, or cardiotonic drugs, central nervous system stimulants, and diuretics.

Abstract: Compounds having activity against chronic obstructive airway disease or cardiac disease, characterized by the formula ##STR1## wherein R.sup.1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R.sup.2 is hydrogen or methyl, provided that R.sup.2 is methyl when R.sup.1 is n-propyl, n-butyl or isobutyl, or a physiologically acceptable salt thereof.

Abstract: The invention refers to compounds having activity against chronic obstructive airway disease or cardiovascular disease, characterized by the formula ##STR1## wherein R.sup.1 is ethyl, n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R.sup.2 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert. butyl, or cyclobutyl provided that R.sup.1 is ethyl when R.sup.2 is methyl, or a physiologically acceptable salt thereof. The invention also refers to processes for the preparation of these compounds, a pharmaceutical preparation containing one of the compounds and a method for the treatment of chronic obstructive airway disease and cardiovascular disease.

Abstract: Alkyl-substituted xanthines having a prevailingly peripheral theophylline-assimilated activity, process for their preparation, pharmaceutical compositions containing said xanthines and their therapeutic use.

Abstract: The invention relates to a process for the preparation of 1,3,7-trialkyl xanthines, i.e. xanthines completely substituted on the nitrogen atoms, by the N-alkylation of xanthines by phase transfer catalysis. Some of the trialkyl xanthines obtained are new and di(3,7-dimethylxanthin-1-yl)methane is described as a medicament having immunosupressant properties.

Abstract: Novel pharmaceutically useful derivatives of selected known bio-affecting carboxylic acids are disclosed, said derivatives having the structural formula ##STR1## wherein R.sub.1 and R.sub.2, which can be the same or different, are each hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.1 -C.sub.5 alkoxy, C.sub.1 -C.sub.5 alkylthio, phenyl, or substituted phenyl having one or more substituents each of which is selected from the group consisting of C.sub.1 -C.sub.5 alkyl, C.sub.1 -C.sub.5 alkoxy, chloro and dialkylamino wherein the alkyl portions, which can be the same or different, each have 1 to 5 carbon atoms, with the proviso that when R.sub.1 is alkoxy or alkylthio, then R.sub.2 cannot be alkoxy or alkylthio; X and X', which can be the same or different, are each hydrogen, C.sub.1 -C.sub.5 alkyl, carboxy, C.sub.2 -C.sub.6 alkoxycarbonyl, halo, C.sub.1 -C.sub.

Abstract: Compounds of the formula ##STR1## or physiologically acceptable salts thereof in which formula R.sup.1 is methyl, ethyl or n-propyl, R.sup.2 is methyl or n-propyl and R.sup.3 is ##STR2## methods for the preparation thereof; intermediates useful for their preparation; pharmaceutical preparations containing at least one of these compounds; and the use thereof in the treatment of allergy and bronchial asthma.

Abstract: A pharmaceutical composition having as an essential ingredient a compound of the formula ##STR1## wherein one to three of R.sup.1, R.sup.2 and R.sup.3 represent an alkenyl group having from 4 to 8 carbon atoms, the other ones are alkyl having from 1 to 12 carbon atoms, and R.sup.1 may also be hydrogen, the compounds themselves and a process for preparing them.

Abstract: There are prepared compounds corresponding to the general formulaT -- Alk -- NH -- CH.sub.2 -- CH(OH) -- CH.sub.

Abstract: Bronchial asthma and other bronchospastic and allergic diseases are treated by administering an effective amount of a substituted xanthine compound having the formula: ##STR1## wherein: R.sub.1 = C.sub.1 -C.sub.3 alkyl,R.sub.3 = c.sub.1 -c.sub.7 alkyl, C.sub.3 -C.sub.7 alkenyl, C.sub.3 -C.sub.7 alkynyl, C.sub.3 -C.sub.7 cycloalkyl or C.sub.4 -C.sub.7 cycloalkylalkyl,R.sub.8 = h, c.sub.1 -c.sub.4 alkyl, C.sub.3 -C.sub.4 alkenyl, C.sub.3 -C.sub.4 alkynyl or C.sub.3 -C.sub.4 cycloalkyl,R = c.sub.1 -c.sub.4 alkyl, 2-halo C.sub.2 -C.sub.3 alkyl, or phenylNovel and preferred bronchodilator and antiallergy compounds are disclosed having the formula ##STR2## wherein: R.sub.1 = C.sub.1 -C.sub.2 alkylR.sub.3 = ch.sub.2 --(c.sub.3 -c.sub.4 alkyl),--CH.sub.2 --(C.sub.3 -C.sub.4 alkenyl), or --CH.sub.2 --(C.sub.3 -C.sub.4 cycloalkyl)R.sub.8 = h, c.sub.1 -c.sub.2 alkyl,R = c.sub.1 -c.sub.4 alkyl, 2-halo C.sub.2 -C.sub.

Abstract: Prolonged bronchodilation and prolonged inhibition of allergic mediator release in mammals are produced by administering an effective amount of a substituted xanthine compound having the formula: ##STR1## wherein: R.sub.1 = methylR.sub.3 = c.sub.4 -c.sub.7 alkyl, C.sub.4 -C.sub.7 cycloalkylalkyl C.sub.4 -C.sub.7 alkenyl, C.sub.4 -C.sub.7 alkynyl, or C.sub.4 -C.sub.7 cycloalkylR.sub.8 = c.sub.1 -c.sub.2 alkylThese compounds are useful in the treatment of bronchial asthma and other bronchospastic and allergic diseases. The compounds are also novel.The bronchodilator and antiallergy agents may be administered in the form of tablets, capsules, aerosols, solutions, suspensions or suppositories.